Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Apr 13;35(4):459–467. doi: 10.1038/onc.2015.97

Fig. 5. Pre-treatment of cancer cells with the MEK inhibitor AZD6244 impairs cancer cell response to AMG655-induced decrease in cell survival (A), cleavage of caspases and PARP (B) and increase in DNA fragmentation (C).

Fig. 5

The given cell lines were pre-treated with 10 μM of the indicated inhibitors for 18 h. After removing medium with the inhibitors, the cells were washed 3 times with medium and then exposed to fresh medium containing different concentrations of AMG655 as indicated (A) or 100 ng/ml (BCPAP and LOXIMVI) or 25 ng/ml (TPC-1) of AMG655 (B and C) for an additional 4 h (B and C) or 15 h (A). The cell numbers were estimated with the SRB assay (A). Protein cleavage was detected with Western blotting (B). DNA fragments were evaluated with Cell Death Detection ELISAPlus kit (C). The data are means of four replicate (A) or triplicate (C) determinations. CF, cleaved form. * P < 0.01; *** P < 0.0001 in comparison with AMG655 alone treatment.